CDK1 and ovarian carcinoma: Since Cdk1 inhibitor JNJ-7706621 was not as selective as SNS-032 in suppressing cell growth between ovarian cancer cell lines with and without elevated CCNE1 expression (Figure 4), our results raise the possibility that a subset of ovarian cancer patients with elevated CCNE1 level may be helped by Cdk2 inhibitors.